Swine Vaccines Market Report 2026

The swine vaccines market size has grown strongly in recent years. It will grow from $2.37 billion in 2025 to $2.6 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to high incidence of viral and bacterial infections in swine, increasing demand for pork products, expansion of commercial pig farming, development of conventional live and inactivated vaccines, rising awareness of swine herd health management.

The swine vaccines market size is expected to see strong growth in the next few years. It will grow to $3.74 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to adoption of dna and recombinant vaccines, increasing government support for swine vaccination programs, growth in precision livestock farming, focus on emerging infectious diseases, expansion of cold-chain infrastructure for vaccine distribution. Major trends in the forecast period include development of multi-valent swine vaccines, focus on preventive swine healthcare, advancements in dna and recombinant vaccines, cold-chain optimized vaccine distribution, rapid response vaccines for emerging swine diseases.

The rising prevalence of diseases in swine is expected to drive the growth of the swine vaccine market in the coming years. Swine diseases refer to any deviations from normal structural or functional conditions in pigs, often accompanied by symptoms, including illnesses such as pseudorabies and influenza. The incidence of swine diseases is increasing due to intensive farming practices that raise animal density, accelerating disease transmission and making outbreaks more difficult to control. Swine vaccines help address this challenge by stimulating the immune system to recognize and respond to specific pathogens, thereby reducing infection rates, mitigating disease severity, and promoting overall herd health. For example, in December 2023, according to the Swine Health Information Center, a US-based organization, Poland reported a concerning rise in African Swine Fever (ASF) cases among wild boars, with 2,347 confirmed cases recorded in early 2023, exceeding the total for 2022. Therefore, the increasing prevalence of swine diseases is expected to propel market growth.

Leading players in the swine vaccine market are focusing on developing innovative vaccines, such as Circumvent CML, to strengthen their competitive position. Circumvent CML is designed to protect swine herds against multiple diseases, enhancing overall health and productivity. For instance, in June 2023, Merck Animal Health, a US-based pharmaceutical company, launched the 3-in-1 swine vaccine Circumvent CML, which protects against Porcine Circovirus Type 2a (PCV-2a), Porcine Circovirus Type 2D (PCV-2d), Mycoplasma hyopneumoniae, and Lawsonia intracellularis. The vaccine builds on Merck’s established antigens and adjuvant systems previously used in Circumvent PCV-M G2 and the standalone Porcilis Ileitis product.

In July 2024, MSD Animal Health, a US-based biopharmaceutical company, acquired Elanco’s aqua business for $1.3 billion. Through this acquisition, MSD Animal Health aims to strengthen its presence in the aquaculture sector by expanding its portfolio of products and solutions that support fish health, welfare, and sustainability. Elanco is a US-based pharmaceutical company specializing in swine vaccine solutions.

Major companies operating in the swine vaccines market are Merck & Co Inc., Boehringer Ingelheim Animal Health USA Inc., Elanco Animal Health Inc., Biogenesis Bago SA, Phibro Animal Health Corporation, KM Biologics Co. Ltd., Hipra Laboratories SA, Ceva Santé Animale SA, Zoetis Inc., Jinyu Bio-Technology Co. Ltd., China Animal Husbandry Industry Co. Ltd., Virbac SA, Harbin Veterinary Research Institute, Bioveta AS, Bimeda Holdings PLC, Biovac Ltd., Hester Biosciences Limited, Hygieia Biological Laboratories, IDT Biologika GmbH, Intervet Inc., Komipharm International Co. Ltd., Kyoritsu Seiyaku Corporation, Lohmann Animal Health International, Norbrook Laboratories Limited, Ouro Fino Saúde Animal SA, Prondil SA, Vaxxinova International BV, Vetoquinol SA, Veyx Pharma GmbH, Tianjin Ringpu Bio-Technology Co. Ltd.

North America was the largest region in the swine vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the swine vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the swine vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the swine vaccines market by increasing the cost of imported vaccine components, plasmid DNA, and recombinant technology kits, causing delays and supply chain disruptions. Regions like North America and Europe, with heavy reliance on imported advanced vaccines, are most impacted, particularly in commercial pig farms and veterinary hospitals. Positively, tariffs incentivize local vaccine manufacturing, encourage development of cost-efficient vaccine solutions, and enhance domestic production capabilities.

The swine vaccines market research report is one of a series of new reports that provides swine vaccines market statistics, including swine vaccines industry global market size, regional shares, competitors with a swine vaccines market share, detailed swine vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the swine vaccines industry. This swine vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A swine vaccine is a formulation given or injected into pigs to provoke an immune response against a particular infectious agent. These vaccines play a vital role in preventing diseases that can adversely affect pig health, productivity, and overall herd management.

The primary types of swine vaccines include attenuated live vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, and recombinant vaccines. Attenuated live vaccines consist of weakened living viruses or bacteria that have been altered to reduce their pathogenicity. These vaccines aim to trigger a robust immune response in pigs by replicating within the body, leading to prolonged immunity. They are effective against various diseases including viral, bacterial, parasitic, and fungal infections. Swine vaccines are distributed through veterinary hospitals, veterinary pharmacies, and online pharmacies. These products are available through government tenders and sales in the market.

The swine vaccine market consists of sales of haemophilus parasuis, pasteurella, salmonella, and streptococcus suis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.